1 Green Flag and 1 Red Flag for Pfizer
Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron, a glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate, showed elevated levels of liver enzymes in some patients.
However, the pharmaceutical company also announced it was going ahead with trials for a different GLP-1-RA candidate, danuglipron, that could be used to treat obesity and Type 2 diabetes.
Neither news item should really matter much in the long term to investors. However, there is one green flag and one red flag that should matter.
Source Fool.com
Pfizer Inc. Stock
€25.63
-2.550%
The stock is one of the favorites of our community with 31 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 60.0% compared to the current price of 25.63 € for Pfizer Inc..
